Rymedi is a technology company.
Rymedi has raised $9.0M across 1 funding round.
Rymedi has raised $9.0M in total across 1 funding round.
Rymedi has raised $9.0M in total across 1 funding round.
Rymedi's investors include RW3 Ventures, White Star Capital, John Lilic.
Rymedi is a health technology company founded in 2017 that builds a blockchain-enabled, cloud-based platform for secure healthcare data management and digital workflows.[1][2][3] It serves life sciences organizations, diagnostic testing companies, clinical research institutions, laboratories, patients, providers, and employers by solving data silos, manual processes, and compliance challenges in precision health, clinical trials, and population health data interoperability.[1][2][3] The platform streamlines patient consent, data collection, reporting, and sharing across parties, ensuring global regulatory compliance while enhancing efficiency and patient-provider connections; it has raised $9M in Series A funding (last round ~1 year ago as of search data) and employs ~21 people, with backing from investors like White Star Capital and RW3 Ventures.[1][2][5]
Rymedi was founded in 2017 (some sources note 2018) by David Stefanich (CEO) in Greenville, South Carolina.[1][2][3][5] The idea emerged amid healthcare data fragmentation, gaining pivotal traction during the 2020 COVID-19 pandemic, when testing centers struggled with siloed systems and outdated tech for mass testing, vaccine efforts, and patient tracking.[3] Early milestones include a 2020 partnership with ATC Healthcare Services for the nation's first integrated COVID-19 testing solution, highlighting its role in crisis response, followed by $9M Series A funding in ~2024 co-led by RW3 Ventures and White Star Capital.[3][5]
Rymedi rides the precision health and digital transformation wave in healthcare, where blockchain addresses exploding demands for secure, interoperable data amid rising clinical trials, diagnostics, and post-pandemic telehealth/tele-testing.[3][6] Timing is ideal as regulatory pressures (e.g., data privacy laws) and market forces like AI-driven personalization favor scalable, compliant platforms over legacy systems, enabling life sciences to handle population-scale data efficiently.[1][2] It influences the ecosystem by fostering collaboration across silos, accelerating trials/testing (as in COVID response), and paving the way for decentralized health marketplaces that boost outcomes and reduce costs.[3][5][6]
Rymedi is poised to expand its Series A-fueled platform into broader precision health applications, leveraging blockchain for AI integrations, global lab networks, and real-world evidence in trials.[1][2][5] Trends like decentralized identity, regulatory tech (RegTech), and value-based care will shape its path, potentially driving acquisitions or further funding amid healthcare's $4T+ digitization push. Its influence may evolve from niche testing enabler to core infrastructure player, redefining patient-centered data flows much like it bridged COVID-era gaps—positioning it as a key connector in fragmented health ecosystems.[3][6]
Rymedi has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Series A in October 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2023 | $9.0M Series A | RW3 Ventures, White Star Capital, John Lilic |